Objectives Lvosimendan on chronic systolic heart failure (CHF)in patients with left ventricular function and exercise tolerance.
Methods Selected 69 patients with different causes of CHF were randomly divided into two groups, control group of 32 patients were treated digitalis, diuretics, giotensin convening enzyme inhibitors and other conventional treatment and Lvosimendan of 37 patients with conventional treatment in the control group Based on the Lvosimendan (0.05 or 0.1ug·kg-1·min-1) for 24 hours. Clinical efficacy (LVEF, CEPT) were observed before and after treatment.
Results one week after treatment, Lvosimendan group Was significantly higher than the total effective rate (P < 0.05). Lvosimendan group of LVEF and VO2MAX than the control group before treatment and increased significantly (P < 0.01 and P < 0.05).
Conclusions Lvosimendan can improve left ventricular function in patients with CHF to improve exercise capacity and VO2MAX, good security.